| Title |
Momordica Charantia lectin exhibits antitumor activity towards hepatocellular carcinoma
|
|---|---|
| Published in |
Investigational New Drugs, September 2014
|
| DOI | 10.1007/s10637-014-0156-8 |
| Pubmed ID | |
| Authors |
Chris Zhiyi Zhang, Evandro Fei Fang, Hai-Tao Zhang, Li-Li Liu, Jing-Ping Yun |
| Abstract |
Background The incidence and mortality of hepatocellular carcinoma (HCC) remain high worldwide. Drug screening from natural plants is one of the potential therapeutic approaches on HCC. Methods The antitumor effect of momordica charantia lectin (MCL) was examined, using MTT, colony formation, AnnexinV/PI staining, western blot and animal model. Results MCL treatment induced G2/M phase arrest, autophagy, DNA fragmentation, mitochondrial injury, and subsequently cell apoptosis in HCC cells. Activation of caspase and MAPK pathway was involved in MCL-induced apoptosis. In vitro and in vivo studies showed that up-regulation of truncated Bid (tBid) upon MCL treatment. Correlation analysis revealed that Bid expression was reversely associated with the IC50 of MCL. Bid suppression using Bid siRNA, BI-6C9 (Bid inhibitor) and Z-IETD-FMK (caspase 8 inhibitor) dramatically attenuated MCL-induced cell proliferation inhibition, caspase 3 activation, ΔΨm depolarization and apoptosis. In addition, combination of MCL and sorafenib exerted stronger lethal activity towards HCC in vitro and in vivo. Conclusion Our data show that the natural compound MCL manifests antitumor activities towards HCC and therefore suggest MCL as a promising chemotherapeutic agent. |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 44 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 24% |
| Student > Master | 10 | 22% |
| Researcher | 5 | 11% |
| Student > Ph. D. Student | 4 | 9% |
| Student > Postgraduate | 3 | 7% |
| Other | 8 | 17% |
| Unknown | 5 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 22% |
| Biochemistry, Genetics and Molecular Biology | 7 | 15% |
| Agricultural and Biological Sciences | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Chemistry | 3 | 7% |
| Other | 8 | 17% |
| Unknown | 9 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2014.
All research outputs
#20,239,689
of 22,766,595 outputs
Outputs from Investigational New Drugs
#977
of 1,168 outputs
Outputs of similar age
#199,993
of 238,624 outputs
Outputs of similar age from Investigational New Drugs
#11
of 12 outputs
Altmetric has tracked 22,766,595 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,168 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,624 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.